Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
322 stopped studies mapped to Chronic Leukemia and descendants · 84% state a reason
Over the 322 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06071624 | Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line… | Phase 1 | suspended | Oct 6, 2023 | Huda Salman | Trial being transferred to new lead site | Other (stated, no rule matched) |
| NCT06597734 | A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in… | Phase 2 | withdrawn | Sep 19, 2024 | M.D. Anderson Cancer Center | PI request | Other (stated, no rule matched) |
| NCT06680661 | ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis | Phase 2 | suspended | Nov 8, 2024 | Leland Metheny | insufficient funding | Funding |
| NCT05377827 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of… | Phase 1 | suspended | May 17, 2022 | Washington University School of Medicine | Drugs/Equipment Unavailable | Other (stated, no rule matched) |
| NCT05400122 | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming… | Phase 1 | suspended | Jun 1, 2022 | David Wald | Drugs unavailable | Other (stated, no rule matched) |
| NCT05828589 | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | Phase 1 | terminated | Apr 25, 2023 | BeOne Medicines | This decision is due to a company business decision with strategy change on the BGB-21447… | Safety / toxicity |
| NCT03146871 | Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or… | Phase 2 | terminated | May 10, 2017 | University of Southern California | Lack of funding | Funding |
| NCT04550442 | Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk… | Phase 1 / Phase 2 | terminated | Sep 16, 2020 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT06630221 | Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations | Phase 2 | suspended | Oct 8, 2024 | Abhay Singh, MD MPH | Funding unavailable | Funding |
| NCT01962636 | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for… | N/A | terminated | Oct 14, 2013 | Masonic Cancer Center, University of Minnesota | No longer a research question to answer. | Other (stated, no rule matched) |
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity… | Phase 2 | terminated | Aug 11, 2017 | Fred Hutchinson Cancer Center | Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and… | Safety / toxicity |
| NCT06662227 | Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors | Early Phase 1 | suspended | Oct 28, 2024 | Wondercel Biotech (ShenZhen) | Because the implementation of the new regulation policy by the Chinese authority | Other (stated, no rule matched) |
| NCT06563804 | A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in… | Phase 1 / Phase 2 | terminated | Aug 21, 2024 | Servier Bio-Innovation LLC | Sponsor decision | Sponsor / business decision |
| NCT03922100 | Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML | Phase 1 / Phase 2 | terminated | Apr 19, 2019 | Nerviano Medical Sciences | Study stopped due to strategic reasons. The decision is not based on specific safety findings as… | Safety / toxicity |
| NCT03547115 | A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell… | Phase 1 | terminated | Jun 6, 2018 | MEI Pharma, Inc. | Business reasons, not related to safety or efficacy results. | Safety / toxicity |
| NCT04953312 | Calprotectin, a Biomarker of COVID-19 Severity (CALPRO)(CALPRO) | N/A | withdrawn | Jul 7, 2021 | Assistance Publique - Hôpitaux de Paris | Abandonment of the study project | Other (stated, no rule matched) |
| NCT03404193 | Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid… | Phase 2 | terminated | Jan 19, 2018 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03514017 | Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia | Phase 2 | terminated | May 2, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Funding unavailable | Funding |
| NCT04160052 | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory… | Phase 1 / Phase 2 | terminated | Nov 12, 2019 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT05316116 | Siltuximab in Large Granular Lymphocytic Leukemia (LGLL) | Early Phase 1 | terminated | Apr 7, 2022 | H. Lee Moffitt Cancer Center and Research Institute | lack of efficacy/futility | Efficacy / futility |
| NCT04809467 | A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in…(topMIND) | Phase 1 / Phase 2 | terminated | Mar 22, 2021 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT04163718 | TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL) | Phase 2 | terminated | Nov 15, 2019 | H. Lee Moffitt Cancer Center and Research Institute | Drug no longer available | Other (stated, no rule matched) |
| NCT03708003 | Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL | Phase 2 | terminated | Oct 16, 2018 | Swiss Cancer Institute | The board decision has been made to conclude the trial ahead of schedule. The primary endpoint has… | Funding |
| NCT04230304 | Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic… | Phase 2 | terminated | Jan 18, 2020 | Mayo Clinic | Slow accrual | Enrollment / accrual |
| NCT05317936 | Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic… | Phase 1 / Phase 2 | terminated | Apr 8, 2022 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT04937166 | A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological… | Phase 1 | terminated | Jun 23, 2021 | Kahr Medical | Slow enrolment | Enrollment / accrual |
| NCT04240704 | Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL | Phase 1 | terminated | Jan 27, 2020 | Novartis Pharmaceuticals | Business, strategic, and development considerations and not due to any safety concerns | Safety / toxicity |
| NCT06343376 | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of… | Phase 1 | terminated | Apr 2, 2024 | Roswell Park Cancer Institute | Manufacturing issues | Drug supply |
| NCT04125290 | US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)(PROXY) | — | terminated | Oct 14, 2019 | AstraZeneca | Study stopped due to lack of recruitment. | Enrollment / accrual |
| NCT05209152 | AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic… | Phase 1 | terminated | Jan 26, 2022 | Amgen | Sponsor decision, unrelated to safety | Safety / toxicity |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell… | Phase 2 | terminated | Nov 7, 2017 | Roswell Park Cancer Institute | Futility analysis determined closure | Efficacy / futility |
| NCT05153330 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With… | Phase 1 | terminated | Dec 10, 2021 | Biomea Fusion Inc. | Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or… | Safety / toxicity |
| NCT06839872 | A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression…(BOSS) | Phase 2 | withdrawn | Feb 21, 2025 | AstraZeneca | AstraZeneca has made the decision to cancel the trial. | Other (stated, no rule matched) |
| NCT05405309 | RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic…(CORONADO CLL) | Phase 1 / Phase 2 | terminated | Jun 6, 2022 | University of Utah | This study was terminated due to sponsor de-activation of all programs associated with RP-3500… | Other (stated, no rule matched) |
| NCT04189952 | Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma | Phase 2 | terminated | Dec 6, 2019 | University of Miami | Investigator Decision | Investigator |
| NCT04752163 | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of… | Phase 1 / Phase 2 | terminated | Feb 12, 2021 | M.D. Anderson Cancer Center | supporting/funding source decided to de-prioritize and stop development of DS-1594 | Funding |
| NCT04685915 | Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL | Phase 2 | withdrawn | Dec 28, 2020 | Inhye Ahn | Bayer is no longer funding due to lack of accrual | Enrollment / accrual |
| NCT03400176 | VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib | Phase 1 | terminated | Jan 17, 2018 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT04694560 | A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and… | — | withdrawn | Jan 5, 2021 | Memorial Sloan Kettering Cancer Center | Lack of potential participants given the other treatment options currently available to people | Other (stated, no rule matched) |
| NCT01532635 | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched… | Phase 2 | terminated | Feb 14, 2012 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT01352312 | Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic… | Phase 1 | terminated | May 11, 2011 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Insufficient accrual over 12 mo period | Enrollment / accrual |
| NCT03492125 | A Study Of The Selective PKC-β Inhibitor MS- 553 | Phase 1 / Phase 2 | terminated | Apr 10, 2018 | MingSight Pharmaceuticals, Inc | The study is terminated due to major protocol revisions. A new study in CLL patients is planned. | Other (stated, no rule matched) |
| NCT03615105 | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA… | Phase 2 | terminated | Aug 3, 2018 | Memorial Sloan Kettering Cancer Center | Low accrual | Enrollment / accrual |
| NCT04553692 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with… | Phase 1 | terminated | Sep 17, 2020 | IGM Biosciences, Inc. | Study terminated due strategic corporate pivot to focus on auto-immune indications | Sponsor / business decision |
| NCT04419389 | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With…(R/R) | Phase 1 / Phase 2 | terminated | Jun 5, 2020 | Aprea Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT03893682 | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's… | Phase 1 | terminated | Mar 28, 2019 | Aptose Biosciences Inc. | Change in corporate strategy | Sponsor / business decision |
| NCT04781855 | Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia… | Phase 1 | withdrawn | Mar 4, 2021 | M.D. Anderson Cancer Center | 0% Participants | Other (stated, no rule matched) |
| NCT04887259 | Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML | Phase 1 | terminated | May 14, 2021 | Lava Therapeutics | The decision to discontinue LAVA-051clinical trial follows a recent review of the competitive… | Safety / toxicity |
| NCT04305444 | Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R… | Phase 2 | terminated | Mar 12, 2020 | Zhejiang DTRM Biopharma | Despite the efforts of our dedicated team and initial progress, we were unable to secure the… | Funding |
| NCT02612311 | Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With…(UNITY-CLL) | Phase 3 | terminated | Nov 23, 2015 | TG Therapeutics, Inc. | Strategic/Business decision | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials